Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 160 | $132.63 | $21,220.80 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $131.26 | $13,126.00 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,635 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $127.98 | $38,394.00 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,735 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $127.98 (range $127.60 to $128.51). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $125.54 | $12,554.00 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,035 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $123.17 | $12,317.00 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,135 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 30, 2015 Filed Jul 31, 2015 17:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $83.36 | $71,689.60 |
DisclosureSEC source: 0001209191-15-063077 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2015 Filed Jul 29, 2015 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-15-062812 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| July 27, 2015 Filed Jul 29, 2015 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 125 | $124.80 | $15,600.00 |
DisclosureSEC source: 0001209191-15-062812 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 27, 2015 Filed Jul 29, 2015 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $123.67 | $49,468.00 |
DisclosureSEC source: 0001209191-15-062812 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $123.67 (range $123.37 to $124.30). Read SEC document |
| July 27, 2015 Filed Jul 29, 2015 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $122.71 | $73,626.00 |
DisclosureSEC source: 0001209191-15-062812 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $122.71 (range $122.31 to $123.25). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2015 Filed Jul 29, 2015 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-15-062812 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2015 Filed Jul 23, 2015 20:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 13,750 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-15-062190 · doc4.xml · derivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2025-07-20 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/21/2015. Read SEC document |
| July 13, 2015 Filed Jul 15, 2015 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-15-060999 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| July 13, 2015 Filed Jul 15, 2015 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $124.48 | $12,448.00 |
DisclosureSEC source: 0001209191-15-060999 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 13, 2015 Filed Jul 15, 2015 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,025 | $123.72 | $126,813.00 |
DisclosureSEC source: 0001209191-15-060999 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $123.72 (range $123.30 to $124.13). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2015 Filed Jul 15, 2015 22:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $51.75 | $58,218.75 |
DisclosureSEC source: 0001209191-15-060999 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2015 Filed May 18, 2015 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 135 | $123.85 | $16,719.75 |
DisclosureSEC source: 0001209191-15-043949 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,289 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · derivative · entry 14 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,179 Underlying: Common Stock · 1,289 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,687 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · derivative · entry 13 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,813 Underlying: Common Stock · 1,687 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $125.20 | $12,520.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 10 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $123.85 | $24,770.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $123.85 (range $123.68 to $124.01). Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $122.90 | $122,900.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,675 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $122.90 (range $122.58 to $123.33). Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,676 | $121.92 | $204,337.92 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,675 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $121.92 (range $121.56 to $122.41). Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,289 | $77.31 | $99,652.59 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,687 | $45.11 | $76,100.57 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · derivative · entry 12 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,375 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| May 04, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 216 | $128.22 | $27,695.52 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $128.22 (range $127.99 to $128.68). Read SEC document |
| May 04, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 332 | $127.09 | $42,193.88 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,591 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $127.09 (range $126.87 to $127.40). Read SEC document |
| May 04, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 577 | $126.15 | $72,788.55 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,923 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $126.15 (range $125.64 to $126.63). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2015 Filed May 6, 2015 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-15-039437 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2015 Filed May 1, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 859 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-15-037993 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,734 Underlying: Common Stock · 859 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| April 30, 2015 Filed May 1, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $125.71 | $25,142.00 |
DisclosureSEC source: 0001209191-15-037993 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.71 (range $125.57 to $125.85). Read SEC document |
| April 30, 2015 Filed May 1, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $123.85 | $61,925.00 |
DisclosureSEC source: 0001209191-15-037993 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,575 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $123.85 (range $123.57 to $124.28). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 30, 2015 Filed May 1, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 159 | $122.41 | $19,463.19 |
DisclosureSEC source: 0001209191-15-037993 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,075 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 30, 2015 Filed May 1, 2015 20:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 859 | $83.36 | $71,606.24 |
DisclosureSEC source: 0001209191-15-037993 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · derivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $134.09 | $13,409.00 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $133.06 | $13,306.00 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $131.60 | $13,160.00 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,575 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $130.57 | $26,114.00 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,675 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $130.57 (range $130.25 to $130.88). Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 625 | $127.95 | $79,968.75 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,875 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $127.95 (range $127.67 to $128.38). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2015 Filed Apr 30, 2015 00:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-15-037168 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2015 Filed Apr 15, 2015 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-15-034290 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Underlying: Common Stock · 1,125 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/13/2011. Read SEC document |
| April 13, 2015 Filed Apr 15, 2015 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,125 | $128.60 | $144,675.00 |
DisclosureSEC source: 0001209191-15-034290 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $128.60 (range $128.12 to $129.09). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2015 Filed Apr 15, 2015 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $51.75 | $58,218.75 |
DisclosureSEC source: 0001209191-15-034290 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $127.45 | $38,235.00 |
DisclosureSEC source: 0001209191-15-028978 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $127.45 (range $127.10 to $128.04). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $125.90 | $138,490.00 |
DisclosureSEC source: 0001209191-15-028978 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,675 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $125.90 (range $125.64 to $126.41). Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 750 | $125.05 | $93,787.50 |
DisclosureSEC source: 0001209191-15-028978 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,775 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $125.05 (range $124.57 to $125.32). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 23, 2015 Filed Mar 24, 2015 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $122.10 | $12,210.00 |
DisclosureSEC source: 0001209191-15-028978 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,525 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,290 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-15-018504 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,468 Underlying: Common Stock · 1,290 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.